51% Decrease In Mortality Rate With Leronlimab/...
Post# of 148187
Why do you say MAV MD is assuming all patients are critical?
Because of his numbers?
Leronlimab death rate in our eIND earlier this year was 14.5%
MAV MD used 17%
MAV MD use a placebo death rate of 34.7%, reports vary presently from 30% to 52% for s/c deaths with SOC.
Regardless, Nader said 87 deaths total, s/c, and thinking is there more critical patients vs severe, but of course not all critical.
We can start with placebo deaths, anywhere from 30% to 50%, then by subtraction get the number of leronlimab deaths. I prefer to start with Leronlimab deaths, and 17% seems like a reasonable number (14.5% old eIND data).
No matter how you do the math, if you start with 87 deaths, even with modest estimates, you end up with a very acceptable % reduction in deaths with leronlimab. Leronlimab in Phase III s/c trials would need to be a different molecule (vs old eIND data) to not to achieve Statistical Significance.